SPONSORED CONTENT
Drugs, Devices, and Decisions
- March 25, 2020
- Posted by Marian R. Graves, DVM
Share:
Understanding your options in managing equine degenerative joint disease (DJD) — Sponsored by American Regent Animal Health
About the Expert:
Marian R. Graves
Marian R. Graves, DVM, earned her veterinary degree from the University of Tennessee in 2000. She completed an internship in equine medicine and surgery at Mississippi State University. Following her internship, Graves engaged in 100% equine practice focused on Western performance and English sport horse. In 2007, Graves transitioned to corporate technical services, where, over the next decade, she participated in several novel equine pharmaceutical and biological product launches. In 2015, she joined American Regent, supporting Adequan, the only FDA-approved PSGAG, and BetaVet, an intra-articular corticosteroid. Her clinical interests include lameness and geriatrics. She will also complete a Juris Doctor in May. Graves has served as program speaker at national and regional veterinary conferences including American Association of Equine Practitioners, Florida Association of Equine Practitioners, The Hambletonian, and Western Veterinary Conference. She has provided an estimated 400 educational seminars and webcasts on equine medical topics.

Written by:
Marian R. Graves, DVM
Related Articles
Stay on top of the most recent Horse Health news with